대원제약

003220KOSPI의약품 제조업

54.1 / 100

Reference Date: 2026-06-10

Financial Score11.0 / 40

News Sentiment18.1 / 25

Momentum15.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is undervalued vs. peers but the high debt ratio poses financial risk. Slightly up 3.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Daewon Pharmaceutical operates in pharmaceuticals, cosmetics, and health functional foods, focusing on CMO services, overseas exports, and the development of OTC drugs and health supplements. Key subsidiaries include Daewon Meditech (hearing aid sales), Daewon Pharmaceutical Vietnam (Southeast Asia market expansion), SD Biotech (cosmetics brand 'SNP'), and 'Ogam Shikdak' (a 2022-launched convenience food brand targeting online markets with products like 'Token Broth').

Number of Employees

1,349people

Average Salary

77.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.934.0Point

PBR

0.86Industry Average 0.894.0Point

In line with industry avg

ROE

-1.44Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

44.70Industry Average 12.430.0Point

3.6x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲7.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼50.1% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 3.7% (declining, 3yr)

Detailed News Sentiment

15 totalPositive 9Neutral 2Negative 4Average Sentiment Score 72.3

Positive
“젠슨 황 테마주부터 비만신약까지”…코어라인·대원·파로스 강세...
젠슨 황의 방한으로 AI 관련 제약바이오주가 강세를 보임.
Positive
'다중 비만약' 개발 경쟁…한미·대원 등 참전
대원제약의 다중 비만약 개발 소식으로 비만 신약 경쟁에서의 경쟁력 강화 기대.
Positive
개화한 다중 비만약 시대…美 릴리 3중제로 관절염 치료, 대원제약도....
대원제약이 다중 비만약 개발에 진출함으로써 비만 및 관절염 치료 분야에서 경쟁력을 강화하고 있다.

Detailed Momentum

52-week position5.0Point

52w mid range (40%)

Current 10,540Won52-week high 14,02052-week low 8,220

1-month return4.0Point

1m +3.33% (slight rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral기업지배구조보고서공시2026-06-01
Neutral분기보고서 (2026.03)2026-05-15